Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience

This retrospective analysis conducted using data from patients enrolled onto the Herceptin Adjuvant has two objectives: The first is to evaluate the impact of the time interval between the end of adjuvant trastuzumab and distant recurrence (TDRI) upon overall survival (OS). The second is to describe...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Breast Cancer Res Treat
Main Authors: Metzger-Filho, Otto, de Azambuja, Evandro, Procter, Marion, Krieguer, Magalie, Smith, Ian, Baselga, Jose, Cameron, David, Untch, Michael, Jackisch, Christian, Bell, Richard, Gianni, Luca, Goldhirsch, Aron, Piccart, Martine, Gelber, Richard D.
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4947530/
https://ncbi.nlm.nih.gov/pubmed/26708471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3656-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares